临床试验/NCT00085280

NCT00085280已完成不适用

A Pilot Study to Determine if Downstream Markers of EGFR Linked Signaling Pathways Predict Response to OSI-774 (Erlotinib) in the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer

National Cancer Institute (NCI)1 个研究点分布在 1 个国家目标入组 129 人开始时间: 2004年9月最近更新: 2014年3月31日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: National Cancer Institute (NCI)
入组人数: 129
试验地点: 1
主要终点: Response rates and distribution of the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (Erk)-phosphorylated expression groups based on the Response Evaluation Criteria in Solid Tumors (RECIST)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This clinical trial is studying how well erlotinib works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

详细描述

PRIMARY OBJECTIVES:

I. Prospectively identify downstream markers of EGFR linked signaling pathways that are predictive of response to OSI-774 (Erlotinib) in this population.

SECONDARY OBJECTIVES:

I. Estimate antitumor objective response rate per RECIST. II. Estimate disease control rate (CR+PR+SD). III. Estimate time to progression and overall survival. IV. Estimate if a grade 2 rash is a predictor of response to OSI-774 (Erlotinib) and of patient survival.

V. Assess safety profile of OSI-774 (Erlotinib) in this population. VI. To determine whether smoking status is linked to outcome for advanced NSCLC patients treated with OSI-774 (Erlotinib).

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients must have pathologically confirmed NSCLC
•Patients must have diagnostic specimen available on paraffin-embedded block
•Patients must have advanced NSCLC (stage IIIB with a malignant pleural effusion or IV disease, or recurrent disease)
•Patients must not have received prior chemotherapy or targeted therapy for metastatic disease, including no prior EGFR inhibitor; patient may have received adjuvant chemotherapy for early stage disease (IB-IIIA), or chemo/XRT for stage IIIA or IIIB disease, provided s/he meets all of the following:
•It has been at least 6 months since completion of patient's adjuvant chemotherapy for early stage disease (IB-IIIA) or chemo/XRT for stage IIIA or IIIB disease
•Patient now has advanced disease
•Patients must have measurable disease per RECIST criteria; all sites of disease must be assessed within 4 weeks prior to registration
•Creatinine < 1.5 mg/dL or a creatinine clearance of > 50 mL/min
•SGOT(AST) and SGPT(ALT) < 2 x the institution's upper limit of normal
•Bilirubin < 1.5 mg/dL
•ANC > 1500/mm^3
•PLT > 100,000/mm^3
•Patients must have ECOG performance status 0, 1, or 2
•Patients with stable, treated brain metastases are eligible (defined as: patients with brain metastases must have been treated and are asymptomatic and are no longer taking corticosteroids)
•Patients with gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease, are ineligible
•Pregnant and breast feeding women are excluded from the study because the agent used in this study may be teratogenic to a fetus and there is no information on the excretion of the agents or their metabolites into breast milk
•Women of childbearing potential and sexually active males must agree to use an accepted and effective method of contraception (hormonal or barrier methods, abstinence) for the duration of the study
•HIV positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with OSI-774 (Erlotinib)
•Patients must not have had immuno, hormonal or radiation therapy within 2 weeks prior to entering the study; those who have not recovered from adverse events due to agents administered more than 2 weeks earlier are ineligible; previously irradiated areas can be considered "measurable disease" if there has been documented progression
•Patients must not have ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements
•Patients must not have serious non-healing wound, or bone fracture, or major surgical procedure within 21 days prior to study entry
•Patients taking Warfarin are eligible
•If the patient is taking Cyp3A4 inducers or inhibitors, they must be discontinued one week prior to starting OSI-774 (Erlotinib)
•Patients must not be enrolled in any other concurrent clinical trials

排除标准

未提供

研究组 & 干预措施

Treatment (erlotinib hydrochloride)

Experimental

Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients complete the Smoking Status Survey, a questionnaire regarding smoking habits, at baseline, and then every 3 months during study treatment.

干预措施: erlotinib hydrochloride (Drug)

Treatment (erlotinib hydrochloride)

Experimental

Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients complete the Smoking Status Survey, a questionnaire regarding smoking habits, at baseline, and then every 3 months during study treatment.

干预措施: laboratory biomarker analysis (Other)

结局指标

主要结局

Response rates and distribution of the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (Erk)-phosphorylated expression groups based on the Response Evaluation Criteria in Solid Tumors (RECIST)

时间窗: Up to 5 years

A Fisher's exact test with a two-sided 5% type I error rate will be calculated.

次要结局

Objective response rate based on the RECIST(Up to 5 years)
Disease control rate (complete response [CR]+partial response [PR]+stable disease [SD])(Up to 8 weeks)
Time to progression(Date of entry on the study to the appearance of new metastatic lesions or objective tumor progression, up to 5 years)
Overall survival(Up to 5 years)
Toxicities associated with erlotinib hydrochloride, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0(Up to 5 years)
Relationship between clinical response and each of the markers using the semiquantitative histo-score method(Baseline)
Effects of smoking status in terms of disease and survival(Up to 5 years)

研究者

发起方

National Cancer Institute (NCI)

申办方类型

Nih

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

终止

2 期

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical ResectionStage IA Non-small Cell Lung CancerStage IB Non-small Cell Lung CancerStage IIA Non-small Cell Lung CancerStage IIB Non-small Cell Lung CancerStage IIIA Non-small Cell Lung Cancer

NCT00087269National Cancer Institute (NCI)110

已完成

1 期

NCT00063895National Cancer Institute (NCI)80

已完成

2 期

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung CancerAdvanced Non Small Cell Lung CancerFailed Prior Chemotherapy

NCT00072631OSI Pharmaceuticals43

已完成

2 期

NCT01664897M.D. Anderson Cancer Center29

已完成

2 期

NCT00749892M.D. Anderson Cancer Center34